| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/0735-1097(94)90581-9 |
| P698 | PubMed publication ID | 8144799 |
| P50 | author | Robert S Gibson | Q108776252 |
| P2093 | author name string | R C Becker | |
| C P Cannon | |||
| N S Kleiman | |||
| J L Anderson | |||
| H S Mueller | |||
| C H McCabe | |||
| J M Haugland | |||
| M J Schweiger | |||
| T D Henry | |||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | plasminogen | Q107129060 |
| thrombolysis | Q1931577 | ||
| acute myocardial infarction | Q18558122 | ||
| heparin | Q190016 | ||
| aspirin | Q18216 | ||
| P304 | page(s) | 993-1003 | |
| P577 | publication date | 1994-04-01 | |
| P1433 | published in | Journal of the American College of Cardiology | Q2984355 |
| P1476 | title | A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial | |
| P478 | volume | 23 |
| Q73295932 | A Randomized, Blinded Study of Two Doses of Novastan(R) (Brand of Argatroban) Versus Heparin as Adjunctive Therapy to Recombinant Tissue Plasminogen Activator (Accelerated Administration) in Acute Myocardial Infarction: Rationale and Design of the M |
| Q71724580 | ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction) |
| Q41609750 | Abrupt vessel closure: changing importance, management, and consequences |
| Q73295830 | Achieving Optimal Reperfusion without Adjunctive Antithrombotic Therapy: Novel Thrombolytic Dosing Strategies |
| Q73245550 | Acute Myocardial Infarction: Antithrombotic Therapy |
| Q79780761 | Acute Myocardial Infarction: Fibrinolytic Therapy |
| Q73599525 | Acute ischemic heart disease |
| Q47316224 | Adjunctive Pharmacologic Treatment: Focus on the Development of Low Molecular Weight Heparins |
| Q33699882 | Advances in antithrombotic therapy of acute myocardial infarction |
| Q33655204 | Advances in the medical management of acute coronary syndromes |
| Q40965786 | Adverse long-term effects of reocclusion after coronary thrombolysis |
| Q41046059 | Antiplatelet and anticoagulant use after myocardial infarction |
| Q33740235 | Antithrombin agents as adjuncts to thrombolytic therapy |
| Q48383360 | Applications of thrombolytic therapy |
| Q77761534 | Bedside activated partial thromboplastin time monitoring: just a matter of time? |
| Q73832105 | Bivalirudin compared with heparin during coronary angioplasty for thrombus-containing lesions |
| Q41668413 | Clinical perspectives on the use of composite endpoints |
| Q71993379 | Clinical pharmacology and drug safety: Lessons from hirudin* |
| Q35566175 | Clinician update: direct thrombin inhibitors in acute coronary syndromes |
| Q40999488 | Clotting for the Clinician: An Overview of Thrombosis and Antithrombotic Therapy |
| Q35873710 | Comparison of desulfatohirudin (REVASC) and heparin as adjuncts to thrombolytic therapy with reteplase in a canine model of coronary thrombosis |
| Q33340032 | Concurrent use of reteplase and lepirudin in the treatment of acute anterior wall myocardial infarction |
| Q40908321 | Coronary Artery Patency and Survival in Clinical Trials |
| Q40601626 | Cost-effectiveness analysis in heart disease, Part III: Ischemia, congestive heart failure, and arrhythmias |
| Q38578862 | Critical analysis of coronary artery bypass graft surgery: a 30-year journey |
| Q73365818 | Current and Practical Management of Acute Myocardial Infarction |
| Q56944923 | Death and nonfatal reinfarction within the first 24 hours after presentation with an acute coronary syndrome: Experience from GUSTO-IIb |
| Q34059396 | Desirudin: a review of its use in the management of thrombotic disorders |
| Q41332329 | Developments in antithrombotic therapy: state of the art anno 1996. |
| Q73286048 | Direct Comparison of Aspirin Plus Hirudin, Aspirin Plus Heparin, and Aspirin Alone Among 12,000 Patients with Acute Myocardial Infarction Not Receiving Thrombolysis: Rationale and Design of the First American Study of Infarct Survival (ASIS-1) |
| Q77535813 | Direct thrombin inhibition and thrombolytic therapy: rationale for the Hirulog and Early Reperfusion/Occlusion (HERO-2) trial |
| Q34027292 | Direct thrombin inhibitors as adjuncts to thrombolytic therapy |
| Q40467552 | Drug interactions with thrombolytic agents. Current perspectives. |
| Q77309612 | Ecarin clotting time but not aPTT correlates with PEG-hirudin plasma activity |
| Q53609143 | Economic evaluation alongside multinational clinical trials. Study considerations for GUSTO IIb. |
| Q73031110 | Efegatran sulfate as an adjunct to streptokinase versus heparin as an adjunct to tissue plasminogen activator in patients with acute myocardial infarction. ESCALAT Investigators |
| Q71974401 | Endogenous and Exogenous Nitric Oxide Protect Against Intracoronary Thrombosis and Reocclusion After Thrombolysis |
| Q73283588 | Enhancing Thrombolysis with Adjunctive Therapy |
| Q71551077 | Frequency of "optimal anticoagulation" for acute myocardial infarction after thrombolysis with front-loaded recombinant tissue-type plasminogen activator and conjunctive therapy with recombinant hirudin (HBW 023). ALKK Study Group |
| Q40466073 | Hirudin and Excess Bleeding Implications For Future Use |
| Q77295099 | Hirudin causes more bleeding than heparin in a rabbit ear bleeding model |
| Q40908310 | Hirudin in Acute Coronary Syndromes: When Cents Override Good Sense |
| Q73295828 | Hirudin in Acute Myocardial Infarction |
| Q47281565 | Hirudin versus heparin and low-molecular-weight heparin: and the winner is... |
| Q33335681 | Hirudin-based anticoagulant strategies for patients with suspected heparin-induced thrombocytopenia undergoing percutaneous coronary interventions and bypass grafting |
| Q73286001 | Hirudin: Its Biology and Clinical Use |
| Q71969316 | Impact of a thrombolysis research trial on time to treatment for acute myocardial infarction in the emergency department |
| Q73286053 | Improving the Efficacy and Stability of Coronary Reperfusion Following Thrombolysis: Exploring the Thrombin Hypothesis |
| Q72360950 | Initial experience with hirudin and streptokinase in acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 6 trial |
| Q47269645 | Low molecular weight heparin (dalteparin) as adjuvant treatment of thrombolysis in acute myocardial infarction--a pilot study: biochemical markers in acute coronary syndromes (BIOMACS II). |
| Q71974509 | Maintenance of Coronary Patency After Fibrinolysis With Tissue Factor Pathway Inhibitor |
| Q77522059 | Medical therapies for the prevention of restenosis after percutaneous coronary interventions |
| Q74787356 | Myocardial infarction: summary of the TIMI trials |
| Q42393055 | New directions in anticoagulant and antiplatelet treatment |
| Q40463597 | Novel Antithrombotic Drugs in Development |
| Q34733975 | Pharmacological properties of hirudin and its derivatives. Potential clinical advantages over heparin |
| Q38547727 | Platelet GP IIb-IIIa Receptor Antagonists in Primary Angioplasty: Back to the Future |
| Q40953733 | Potential for a New Coronary Thrombolytic Plateau |
| Q33735559 | Prehospital thrombolysis: an idea whose time has come |
| Q33359976 | Prevention of venous thromboembolism following orthopaedic surgery: clinical potential of direct thrombin inhibitors |
| Q73744494 | Prospective validation of a composite end point in thrombolytic trials of acute myocardial infarction (TIMI 4 and 5). Thrombosis In Myocardial Infarction |
| Q35654775 | Recent advances in the treatment of acute myocardial infarction |
| Q71025487 | Recombinant hirudin for prevention of experimental postoperative intraocular fibrin |
| Q73180183 | Recombinant hirudin prevents postoperative fibrin formation after experimental cataract surgery |
| Q73365802 | Reexamination of the Thrombin Hypothesis: What We Have Learned from TIMI 9B and GUSTO IIb |
| Q71974513 | Role of Thrombin Compared With Factor Xa in the Procoagulant Activity of Whole Blood Clots |
| Q77926538 | Safety of coronary stenting early after thrombolysis in patients with acute myocardial infarction: one- and six-month clinical and angiographic evolution |
| Q56945316 | Selective Inhibition of Factor Xa Is More Efficient Than Factor VIIa–Tissue Factor Complex Blockade at Facilitating Coronary Thrombolysis in the Canine Model |
| Q73614678 | Significance of the Thrombolysis in Myocardial Infarction scoring system in assessing infarct-related artery reperfusion and mortality rates after acute myocardial infarction |
| Q73914243 | Sixty-minute alteplase protocol: a new accelerated recombinant tissue-type plasminogen activator regimen for thrombolysis in acute myocardial infarction |
| Q73365795 | The Narrow Therapeutic Index of Thrombin Inhibition: Implications for Newer Antithrombotic Therapies |
| Q35088077 | The evolving role of direct thrombin inhibitors in acute coronary syndromes |
| Q40966580 | The promise of new genetically engineered plasminogen activators |
| Q52533632 | Therapeutic inhibition of thrombin activities, receptors, and production. |
| Q73681259 | Thrombin Generation in Patients with Acute Myocardial Infarction Treated with Front-Loaded rt-PA and Recombinant Hirudin (HBW 023) |
| Q73365798 | Thrombin Hypothesis: The TIMI 9B and GUSTO IIB Trials Have Successfully Disproven/Proven the Thrombin Hypothesis |
| Q40430452 | Thrombin Inhibitors in Acute Myocardial Infarction |
| Q78035754 | Thrombin inhibitors suppress the thrombin-thrombomodulin-mediated generation of activated protein C |
| Q73681264 | Thrombin: Structure, Biochemistry, Measurement, and Status in Clinical Medicine |
| Q73365810 | Thrombolytic Therapy: The Treatment of Choice in Acute Myocardial Infarction |
| Q40433424 | Thrombolytic and antithrombotic treatment in myocardial infarction: main achievements and future perspectives |
| Q72774776 | Thrombolytic therapy in acute myocardial infarction--selected recent developments |
| Q73286007 | Time as an Adjunctive Agent to Thrombolytic Therapy |
| Q73283579 | Time to Reperfusion: The Critical Modulator in Thrombolysis and Primary Angioplasty |
| Q53993017 | Time to Treatment: A Crucial Factor in Thrombolysis and Primary Angioplasty. |
| Q77761566 | Trends in the use of pharmacotherapies for acute myocardial infarction among physicians who design and/or implement randomized trials versus physicians in routine clinical practice: the MILIS-TIMI experience. Multicenter Investigation on Limitation |
| Q57798992 | Usefulness of fibrinogenolytic and procoagulant markers during thrombolytic therapy in predicting clinical outcomes in acute myocardial infarction |
| Q73446080 | [Direct thrombin inhibitors: their role in the treatment of arterial and venous thrombosis] |
| Q74521066 | [Optimization of thrombolytic treatment in acute myocardial infarct: the role of new fibrinoselective drugs and their combination with new antithrombotics] |
Search more.